Bioventix PLC (LON:BVXP) insider Ian James Nicholson sold 2,000 shares of Bioventix PLC stock in a transaction dated Friday, November 18th. The stock was sold at an average price of GBX 1,300 ($16.24), for a total value of £26,000 ($32,483.76).

Bioventix PLC (LON:BVXP) opened at 1375.00 on Wednesday. Bioventix PLC has a one year low of GBX 899.50 and a one year high of GBX 1,600.00. The firm’s market capitalization is GBX 69.44 million. The firm has a 50-day moving average price of GBX 1,351.34 and a 200-day moving average price of GBX 1,112.03.

The business also recently declared a dividend, which was paid on Friday, November 11th. Shareholders of record on Thursday, October 27th were given a GBX 46 ($0.57) dividend. The ex-dividend date of this dividend was Thursday, October 27th. This represents a yield of 3.15%. This is a positive change from Bioventix PLC’s previous dividend of $16.50.

Separately, FinnCap boosted their price target on Bioventix PLC from GBX 1,350 ($16.87) to GBX 1,450 ($18.12) and gave the company a “corporate” rating in a report on Monday, October 17th.

WARNING: “Ian James Nicholson Sells 2,000 Shares of Bioventix PLC (BVXP) Stock” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another website, it was illegally stolen and republished in violation of U.S. & international trademark & copyright law. The legal version of this article can be read at

Bioventix PLC Company Profile

Bioventix PLC, based in the United Kingdom, is engaged in the development and supply of antibodies. The Company is a biotechnology company specializing in the development of high-affinity sheep monoclonal antibodies (SMAs) for use in immunodiagnostics focusing on the areas of clinical diagnostics and drugs of abuse testing.

Receive News & Stock Ratings for Bioventix PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioventix PLC and related stocks with our FREE daily email newsletter.